ALIAXIN GP Injection Solution for

What is ALIAXIN GP

ALIAXIN GP (Global Performance) is a sterile, monophasic dermal filler containing **cross-linked hyaluronic acid** at 25 mg/mL. It's delivered in two pre-filled 1 mL syringes, accompanied by four sterile needles (27G ×13 mm and 27G ×19 mm) :contentReference[oaicite:1]{index=1}.

• Type: Non-animal-derived, pharmaceutically pure, viscoelastic gel designed for intradermal/subcutaneous application.
• Indications: Correction of moderate-to-deep facial wrinkles (e.g., nasolabial folds, marionette lines), volume restoration in cheeks, chin, and lips, and treatment of acne scars :contentReference[oaicite:2]{index=2}.
• Benefits: Monophasic formula ensures smooth tissue integration; reliable results lasting 6–12 months :contentReference[oaicite:3]{index=3}.
• Advantages: High cohesivity, balance of hydration, voluminous lift, and soft, natural outcomes :contentReference[oaicite:4]{index=4}.

ALIAXIN GP is a versatile filler used by aesthetic professionals to restore facial volume and contour while maintaining natural facial expression and feel.

How to use ALIAXIN GP

Administration of ALIAXIN GP must be performed by qualified medical professionals under aseptic conditions.

• Preparation: Inspect packaging/syringe for damage; cleanse skin with alcohol-based disinfectant; avoid benzalkonium chloride :contentReference[oaicite:5]{index=5}.
• Injection technique: Use needles or cannulas. Inject into mid-to-deep dermis or subcutaneous plane using linear threading, bolus, or fanning techniques depending on anatomy and area :contentReference[oaicite:6]{index=6}.
• Treated areas: Nasolabial folds, marionette lines, glabellar folds, chin, cheeks, forehead, and lips :contentReference[oaicite:7]{index=7}.
• Dosage: Typically 1 mL per syringe per session; practitioners may use both syringes depending on targeted area volume :contentReference[oaicite:8]{index=8}.
• Post-procedure: Gentle massage, ice application, avoid strenuous activity/makeup for 24 hours :contentReference[oaicite:9]{index=9}.
• Follow-up: Assess results in 2–4 weeks; touch-ups may be performed if necessary.
• Documentation: Record batch numbers, injection sites, volumes for traceability per medical device protocols :contentReference[oaicite:10]{index=10}.

Precision, hygiene, and documentation are essential to ensure patient safety and predictable outcomes.

Mode of Action ALIAXIN GP

ALIAXIN GP operates through physical and biochemical mechanisms:

• Mechanical support: Cross-linked HA gel provides structural volume in dermis, smoothing wrinkles and restoring contours :contentReference[oaicite:11]{index=11}.
• Hydration: HA retains up to 1,000× its weight in water, enhancing skin hydration and elasticity :contentReference[oaicite:12]{index=12}.
• Tissue integration: Monophasic HA blends with tissue, minimizing nodules and creating a natural feel :contentReference[oaicite:13]{index=13}.
• Stimulation: HA may promote collagen synthesis, strengthening extracellular matrix and improving skin quality :contentReference[oaicite:14]{index=14}.
• Biodegradation: HA is enzymatically broken down, with visible effects lasting approximately 6–12 months :contentReference[oaicite:15]{index=15}.

The combination of volume restoration and hydration improves both cosmetic appearance and tissue health.

ALIAXIN GP Interactions ALIAXIN GP

Due to its localized application, ALIAXIN GP shows minimal systemic drug interactions, but several local considerations are essential.

• Antiseptics: Avoid benzalkonium chloride to prevent HA precipitation; alcohol-based solutions are recommended :contentReference[oaicite:16]{index=16}.
• Anticoagulants/antiplatelets: May increase bruising or bleeding risk after injection :contentReference[oaicite:17]{index=17}.
• NSAIDs/aspirin: Can exacerbate bleeding/bruising post-injection.
• Concurrent aesthetic procedures: Delay chemical peels, laser treatments, or microdermabrasion near injection site for ≥1 week :contentReference[oaicite:18]{index=18}.
• Hyaluronidase: Can reverse HA, used in complication management (e.g., vascular compromise) :contentReference[oaicite:19]{index=19}.
• Vaccinations: Avoid facial filler injection at same site around vaccine administration; monitor for inflammation :contentReference[oaicite:20]{index=20}.

Proper planning around co-medications and procedures ensures safety and recovery ease.

Dosage of ALIAXIN GP

• Volume: 1 mL per syringe; two syringes may be used across multiple zones per session :contentReference[oaicite:21]{index=21}.
• Injection depth: Mid-to-deep dermal or subcutaneous layer depending on area—deeper for volume, superficial for fine lines :contentReference[oaicite:22]{index=22}.
• Treated areas & typical dosing:
  • Nasolabial folds / marionette lines: 0.5–1 mL per side.
  • Cheeks/chin: 0.5–2 mL depending on volume deficit.
  • Lips: small aliquots for natural shape, typically ≤1 mL.
• Session plan: Single treatment with optional enhancement in 2–4 weeks.
• Maintenance: Repeat every 6–12 months based on degradation and patient needs :contentReference[oaicite:23]{index=23}.
• Safety measure: Avoid intravascular injection; aspirate before injecting; inject slowly.

A nuanced dosing strategy ensures natural, effective, and safe aesthetic outcomes.

Possible side effects of ALIAXIN GP

ALIAXIN GP is well tolerated. Most adverse effects are localized and transient:

• Common (within 24–72 hrs): Redness, mild swelling, bruising, tenderness, itch—typically resolve in ≤1 week :contentReference[oaicite:24]{index=24}.
• Less common: Localized lumps or nodules; usually resolve or can be massaged out; possible sterile granulomas; infection is rare :contentReference[oaicite:25]{index=25}.
• Serious (rare): Vascular occlusion (vision loss, skin necrosis), allergic reactions—require immediate management :contentReference[oaicite:26]{index=26}.
• General: Headache, temporary discomfort at injection sites.

Practitioners should monitor for red flags and manage complications promptly, including use of hyaluronidase if vascular compromise occurs.

ALIAXIN GP Contraindications ALIAXIN GP

• Absolute:
  • Known hypersensitivity to HA or lidocaine (if included) :contentReference[oaicite:27]{index=27}.
  • Active infection or inflammation at treatment site :contentReference[oaicite:28]{index=28}.
  • Bleeding disorders / anticoagulant therapy – relative contraindication :contentReference[oaicite:29]{index=29}.
• Relative:
  • Pregnancy or breastfeeding – safety data limited :contentReference[oaicite:30]{index=30}.
  • Autoimmune disorders – clinical judgment needed.
  • History of keloid or poor wound healing.
  • Recent facial cosmetic procedures – allow healing before injection.

Proper screening is key for safe application and reduced complication risks.

Storage of ALIAXIN GP

• Temperature: Store between 2 °C and 28 °C (ideally 2–25 °C); do not freeze :contentReference[oaicite:31]{index=31}.
• Packaging: Keep in original sealed blister until use; protect from light and moisture.
• Sterility: Single-use syringes; dispose of any unused content.
• Expiry: Use before printed date; discard open or expired product.
• Disposal: Sharps and materials should be disposed in appropriate medical waste containers.

Following storage guidelines preserves the gel’s quality and ensures safe use.